PORTFOLIO N° 04 · BPC-157
A pentadecapeptide studied in rats. Not a script your doctor can write.
Nineteen studies, one cancelled clinical trial, and a regulatory calendar that may change things by late 2026. Here is what the literature actually says.
The short version
BPC-157 is a 15-amino-acid research peptide derived from a protein in human gastric juice. Almost all of what is known about it comes from rodent studies — where the consistency of results across tendon, gut, nerve, and organ models is striking — with only a handful of small human pilot studies to date. It is not FDA-approved for any use and carries no approved prescription pathway in the United States. The research is more interesting, and the evidence more unresolved, than either enthusiasts or skeptics tend to present. This brief covers the mechanism, the animal data, the three human pilots, and the regulatory situation as of 2026. For reported real-world experiences and safety considerations, see the effects page.
What is BPC-157?
BPC-157 — Body Protection Compound 157 — is a synthetic pentadecapeptide: fifteen amino acids in a fixed sequence derived from a partial region of the human gastric body protection compound protein. Its molecular weight is 1,419.5 daltons and its CAS number is 137525-51-0. In research databases it also appears under the synonyms PL 14736, PL-10, PLD-116, BPC 157 acetate, and BPC 157 free base — the clinical-trial designations used during a Croatian pharmaceutical development program that ultimately did not produce a licensed drug.
The peptide is unusual among research compounds in one straightforward respect: it is stable in human gastric juice for more than 24 hours [1]. Most peptides degrade within minutes of contact with gastric acid. BPC-157 does not, which is consistent with its origin — it was identified in a protein found in gastric juice, and the body appears to have optimized that protein for exactly that environment. This stability is what makes oral and intragastric dosing routes plausible in rodent studies; it is not, by itself, evidence of efficacy in any system.
The research literature on BPC-157 is large in volume but narrow in origin. The overwhelming majority of preclinical publications — in tendon, ligament, bone, muscle, gastrointestinal, neurological, and vascular injury models — come from a single research group at the University of Zagreb led by Predrag Sikiric and Sven Seiwerth. That concentration is worth noting before reading anything else on this site. Independent replication exists but is limited. A 2025 systematic review identified 544 articles in an initial search and included 36 after screening [2], suggesting a literature broader than a single group, but the Zagreb group's studies constitute a disproportionate share of the foundational preclinical evidence.
The domain name you arrived at — bpc157script.com — implies a question: can a physician write a prescription for this compound? The answer is not a simple no. It is a more specific no, with a regulatory timeline attached. BPC-157 is not FDA-approved for any human indication. The concept of 'off-label prescribing' — which governs how physicians use approved drugs for unapproved uses — is legally inapplicable to unapproved new drugs. A physician administering BPC-157 outside an FDA-authorized Investigational New Drug (IND) framework is administering an unapproved new drug, which carries distinct legal and liability implications [3]. The regulatory picture changed in April 2026 and will be reviewed again in late July 2026. We cover that fully in the FAQ and the dosage brief.
What the research has studied
The preclinical literature covers a wider terrain than most people arriving at this domain expect. BPC-157 has been studied in rodent models of tendon transection, ligament rupture, muscle crush injury, segmental bone defect, gastric ulceration, colitis and ischemia-reperfusion, spinal cord compression, traumatic brain injury, and stroke. It has been applied intraperitoneally, subcutaneously, intramuscularly, intravenously, orally, topically, intragastrically, intra-articularly, and intravesicularly. Across this range of models and routes, the literature consistently reports accelerated healing of structural tissue and cytoprotection of epithelial and parenchymal tissue.
In musculoskeletal injury models specifically: a 2025 systematic review covering 35 preclinical studies and one human retrospective confirmed functional, structural, and biomechanical improvements across muscle, tendon, ligament, and bone injury in animals [4]. In rats with surgically detached quadriceps muscles, oral BPC-157 at 10 μg/kg per day enabled complete muscle-to-bone reattachment confirmed by MRI and ultrasound by day 21–28, while saline controls showed a persistent 4.1 mm gap and permanent healing failure [5]. In a ligament healing study, intraperitoneal doses of 10 μg/kg or 10 ng/kg daily improved biomechanical tensile strength, collagen organization, and macroscopic appearance through 90 days post-transection [6].
In gastrointestinal models: intramuscular BPC-157 at 800 ng/kg reduced gastric ulcer area by 45–66% across three rat ulcer models, matching or exceeding the protective efficacy of famotidine [7]. Orally administered BPC-157 at 10 μg/kg restored blood supply to ischemic colon segments, normalized nitric oxide and malondialdehyde levels, and preserved mucosal integrity in colitis-ischemia-reperfusion models [8].
In neurological models: BPC-157 counteracted dopamine receptor blockade, nigrostriatal damage, and schizophrenia-like symptoms in rat models, and a single intraperitoneal injection of 2 μg/kg administered 10 minutes after spinal cord compression in rats improved motor function and resolved spasticity by day 15, with functional benefits sustained through day 360 [9] [10].
Human data is an entirely different matter. Three small, uncontrolled pilot studies exist: a retrospective series of 12 patients with chronic knee pain who received intra-articular injections (7 of 12 reported relief lasting more than 6 months); a 12-patient interstitial cystitis pilot (all 12 reported 80–100% symptom resolution at 6 weeks after intravesicular injection of 10 mg); and an IRB-approved intravenous safety and pharmacokinetics study in 2 healthy adults who received up to 20 mg IV infusion with no adverse events and no clinically meaningful changes in any biomarker [4] [2]. None of these are randomized controlled trials. Taken together, they establish that human administration has not produced the adverse events one might expect extrapolating from an unapproved compound — they do not establish efficacy for any condition.
Mechanism: what the peptide appears to do
BPC-157's preclinical activity has been attributed to simultaneous engagement of several overlapping repair pathways. VEGFR2 upregulation drives angiogenesis — the formation of new blood vessels — in ischemic and injured tissue [11]. The Akt-eNOS axis increases nitric oxide synthesis, supporting vasodilation and endothelial repair. FAK-paxillin signaling promotes fibroblast migration and collagen synthesis in tendon and ligament models. ERK1/2 activation accelerates early-phase gene expression cascades within minutes of application — Akt1, VEGFA, Mapk1, and FAK/Ptk2 have all been detected in this early cascade [12]. JAK2-STAT signaling mediates growth hormone receptor upregulation: in rat tendon fibroblasts, BPC-157 at concentrations of 0.1–0.5 μg/mL increased growth hormone receptor mRNA and protein expression up to sevenfold by day 3 [13].
BPC-157 also modulates cytokine profiles — specifically, it reduces pro-inflammatory signals including TNF-alpha, IL-6, and IFN-gamma in musculoskeletal injury models [2]. In the brain-gut axis, it modulates serotonergic, dopaminergic, and GABAergic pathways simultaneously; studies measuring regional serotonin synthesis rates via autoradiography found BPC-157 at 10 μg/kg intraperitoneally significantly altered 5-HT synthesis rates in the dorsal thalamus, hippocampus, hypothalamus, and substantia nigra [14].
The scope of these mechanisms — angiogenesis, anti-inflammation, fibroblast activation, neurotransmitter modulation, nitric oxide normalization — is simultaneously what makes the literature interesting and what makes translating it difficult. A compound with this breadth of reported preclinical activity either represents a genuine multi-pathway repair signal or reflects the interpretive flexibility of preclinical models produced primarily by one research group. The honest position — the one the literature warrants — is uncertainty. Promising and unverified are both true.
Why this site exists
BPC-157 Script is an independent editorial project. We summarize the peer-reviewed research literature on BPC-157 for readers who want to understand what the science actually says — without the sales framing of peptide vendors or the reflexive dismissal of commentators who have not read the studies. We are not a clinic. We do not provide medical advice. We are not a pharmacy and do not distribute or refer to any product.
The domain name is an editorial position. 'Script' — shorthand for prescription — is the question the visitor arrives with. The site's job is to answer it honestly: the science is more interesting than most people know, the regulatory situation is genuinely in motion as of 2026, and the answer to 'can I get a prescription for this?' is currently no, for reasons that are specific and documented and worth understanding rather than simply accepting. Each page of this brief addresses a different dimension of that answer. The research page covers mechanism and key studies. The dosage page covers what research doses looked like in animal models and what the pharmacokinetics tell us. The regulatory section of the FAQ covers the 503A compounding history, the PCAC meeting scheduled for July 2026, and what happens if the committee recommends Category 1 inclusion.